Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)

NCT03723655 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT03723655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03723655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 2/3
Overall status
Completed
Start date
September 27, 2018
Completion date
January 16, 2026
Enrollment
314 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

hypertrophic cardiomyopathy, non-obstructive hypertrophic cardiomyopathy, obstructive hypertrophic cardiomyopathy